Comparable efficacy and safety of generic and branded imatinib for patients with chronic myeloid leukemia in China

Background: Generics imatinib became an alternative treatment option for chronic myeloid leukemia (CML) patients in China. However, clinicians and patients alike harbor concerns regarding the long-term safety of generic imatinib. Objectives: Patients with chronic phase CML receiving frontline imatin...

Full description

Bibliographic Details
Published in:	Therapeutic Advances in Hematology
Main Authors:	Fang Cheng, Di Wu, Zheng Cui, Qiang Li, Weiming Li, Yu Zhang
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-08-01
Online Access:	https://doi.org/10.1177/20406207241270806

Similar Items

Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China
by: Fang Cheng, et al.
Published: (2023-05-01)

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
by: Iman Abou Dalle, et al.
Published: (2019-11-01)

The efficacy of generic imatinib in patients with chronic myeloid leukemia: A single centre experience
by: Urošević Ivana, et al.
Published: (2021-01-01)

Generic Imatinib Mesylate as first-line treatment of chronic myeloid leukemia.
by: Brahim Benzineb, et al.
Published: (2023-04-01)

Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study
by: Adi J. Klil-Drori, et al.
Published: (2019-07-01)

EFFECT OF FREQUENT GENERIC IMATINIB SWITCHING ON TREATMENT RESPONSE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
by: Murat Çınarsoy, et al.
Published: (2024-12-01)

Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice
by: A. K. Golenkov, et al.
Published: (2014-07-01)

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01)

Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature
by: Asiyeh Amouei, et al.
Published: (2021-04-01)

Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
by: Demet Çekdemir, et al.
Published: (2020-03-01)

Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
by: Ali Ibrahim, et al.
Published: (2022-05-01)

Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience
by: Josephine A. Adattini, et al.
Published: (2022-10-01)

Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea
by: Parveen Jain, et al.
Published: (2013-01-01)

OUTCOME OF FRONTLINE TREATMENT WITH “GENERIC” IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY
by: Mohamed Amine BEKADJA
Published: (2017-10-01)

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings
by: Fang Cheng, et al.
Published: (2023-04-01)

Adverse effects of Imatinib in patients with chronic myeloid leukemia
by: Hajar Masrour, et al.
Published: (2023-01-01)

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
by: Naoto Takahashi, et al.
Published: (2012-06-01)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
by: Radhakrishnan Ramchandren, et al.
Published: (2009-05-01)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
by: Darlize Hübner Martins, et al.
Published: (2011-01-01)

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
by: Wendy Deenik, et al.
Published: (2010-06-01)

Chronic myeloid leukemia — before and after imatinib (First part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Chronic myeloid leukemia — before and after imatinib (part II)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

OUR EXPERIENCE IN TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Marjana Glaser, et al.
Published: (2004-04-01)

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al.

Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.
by: Zheng Hu, et al.
Published: (2009-01-01)

Pharmaceutical inhibition of BCL6 ameliorates resistance to imatinib in chronic myeloid leukemia
by: Yingying Xiao, et al.
Published: (2024-08-01)

Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data
by: Petra Belohlavkova, et al.
Published: (2024-09-01)

Long-Term Safety and Efficacy of Imatinib in Chronic Myeloid Leukemia: Real-World Evidence from a Single-Center Study
by: İsmail Can Kendir, et al.
Published: (2025-06-01)

Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment
by: Federico Angriman, et al.
Published: (2015-05-01)

Gynecomastia in a Boy with Chronic Myeloid Leukemia during Imatinib Therapy
by: Betül Tavil, et al.
Published: (2013-09-01)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
by: Jovita Martin, et al.
Published: (2011-01-01)

Effect of Imatinib on Bone Marrow Morphology and Angiogenesis in Chronic Myeloid Leukemia
by: Neetu Pandey, et al.
Published: (2019-01-01)

Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia
by: Stéphane Flamant, et al.
Published: (2010-08-01)

Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy
by: Rick Proschmann, et al.
Published: (2017-02-01)

Influence of late treatment on how chronic myeloid leukemia responds to imatinib
by: Ana Carolina Costa Scerni, et al.
Published: (2009-01-01)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
by: Rafiyath Shamudheen, et al.
Published: (2010-11-01)

Kaposi’s sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy
by: Matteo D’Addona, et al.
Published: (2022-06-01)